Therapeutics News and Research

RSS

Guided Therapeutics to launch LightTouch non-invasive cancer detection technology at Medica 2009

Guided Therapeutics, Inc. (GT) today announced plans to introduce its LightTouch™ non-invasive cancer detection technology at Medica 2009 in Düsseldorf, Germany November 18 - 20, 2009.

2 Nov 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

2 Nov 2009

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l’Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study’s main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.

2 Nov 2009

Scientists report a major step forward in the development of an effective therapy against Nipah virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

31 Oct 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

iCo Therapeutics announces $4,000,000 brokered private placement

iCo Therapeutics Inc. (the "Company") is pleased to announce that further to its press release issued October 20, 2009 announcing a $4,000,000 brokered private placement (the "Offering") co-led by Loewen, Ondaatje, McCutcheon Limited and Versant Partners Inc. (collectively, the "Agents"), the Company has completed the first tranche of the Offering through the issuance of 6,000,000 common shares of Company (the "Shares"). The Shares were issued at a price of $0.48 per share for gross proceeds of $2,880,000.

31 Oct 2009

FDA approves an expanded indication for BYETTA injection

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes.

31 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Repros Therapeutics signs settlement agreement with major creditors

Repros Therapeutics today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Monash University physiologist honored with Life Scientist of the Year award

A Monash University physiologist, whose research into weight management, obesity and diabetes has led to significant medical breakthroughs and drug design, has been awarded one of the nation's top research honours.

30 Oct 2009

Echo Therapeutics enhances its needle-free Symphony tCGM biosensor

Echo Therapeutics, Inc., a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has made significant advances to the development of its needle-free Symphony tCGM biosensor.

30 Oct 2009

Women face higher risk of graft loss after liver transplantation compared to men

Although women with chronic hepatitis C virus (HCV) infection are at lower risk for developing cirrhosis, researchers who compared outcomes for men and women after having liver transplantation found that women have a significantly increased risk of overall graft loss and graft loss from recurrent HCV than men.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

MRG: Global spinal nonfusion technology market to increase up to $2 billion

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the global spinal nonfusion technology market will increase from approximately $400 million in 2008 to almost $2 billion by 2013.

30 Oct 2009

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, today announced they have entered into an exclusive partnership for the commercialization of Caldolor® (ibuprofen) Injection in Australia and New Zealand.

30 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

AstraZeneca, Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.

29 Oct 2009

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.

29 Oct 2009

Therapeutics News and Research

Guided Therapeutics to launch LightTouch non-invasive cancer detection technology at Medica 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

Scientists report a major step forward in the development of an effective therapy against Nipah virus

Shire announces third quarter 2009 financial results

iCo Therapeutics announces $4,000,000 brokered private placement

FDA approves an expanded indication for BYETTA injection

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Repros Therapeutics signs settlement agreement with major creditors

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Monash University physiologist honored with Life Scientist of the Year award

Echo Therapeutics enhances its needle-free Symphony tCGM biosensor

Women face higher risk of graft loss after liver transplantation compared to men

Study: HSP inhibitor could stop tumor formation and extend survival

MRG: Global spinal nonfusion technology market to increase up to $2 billion

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News